Antares Phar­ma wins FDA OK for oral testos­terone treat­ment; Eye-fo­cused biotech re­ports PhI­II da­ta for pupil di­la­tion drug

Antares Phar­ma has nabbed an­oth­er FDA ap­proval, and the com­pa­ny’s sec­ond in­volv­ing testos­terone.

The New Jer­sey phar­ma an­nounced the com­pa­ny’s ap­proval on Tues­day for Tlando, aka testos­terone un­de­canoate, an oral treat­ment for testos­terone re­place­ment ther­a­py. Ac­cord­ing to the phar­ma, the drug is in­di­cat­ed for con­di­tions as­so­ci­at­ed with a de­fi­cien­cy or ab­sence of en­doge­nous testos­terone, or hy­pog­o­nadism.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER